Non-Small Cell Lung Cancer (NSCLC) Treatment Market: By Drug Class (Angiogenesis Inhibitors, Epidermal Growth Factor Receptor Blockers, Kinase Inhibitors, Microtubule Stabilizers, Folate Antimetabolites, and PD-1/ PD-L1 Inhibitors), By Application (Large Cell (Undifferentiated) Carcinoma, Squamous Cell (Epidermoid) Carcinoma, Adenocarcinoma, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The global non-small cell lung cancer (NSCLC) treatment market was valued at US$ XX Mn in 2021 and is expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2022 to 2026. Lung cancer usually starts when cells of the lung become abnormal and begin to grow out of control. With the uncontrolled growth of the cancer cells, forms the tumor which tend to spread to the other parts of the body. There are two types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), whereas 10% to 15% are small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is a cell lining air passage, characterized by abnormal cell growth in lung tissue. Depending on the stage of the cancer, there are various treatment options that are available, which include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Key developments in Non-Small Cell Lung Cancer (NSCLC) Treatment Market In February 2018, AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small-cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

Non Small Cell Lung Cancer Nsclc Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Drivers And Restraints

Increase in the prevalence of lung cancer is majorly driving the non-small cell lung cancer (NSCLC) treatment market. The growing awareness about the lung cancer diagnosis, treatment and the support from the government organizations expected to enhance the growth of the non-small cell lung cancer (NSCLC) treatment market. The adoption of the unhealthy lifestyle is also adding fuel for to the growth of the market. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012 and according to American Society of cancer, non-small cell lung cancer accounts for ~85% to 90% of overall lung cancer cases. Owing to the larger patient pool, the non-small cell lung cancer (NSCLC) treatment market is expected to exhibit growth over the forecast period. However, the limited treatment options, and the availability of the generic drugs are likely to hinder the growth of the non-small cell lung cancer (NSCLC) treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Non Small Cell Lung Cancer Nsclc Treatment Market Segmentation

drug class
  • Microtubule Stabilizer
    • Paclitaxel Protein Bound
    • Docetaxel
  • Angiogenesis Inhibitors
    • Bevacizumab
    • Ramucirumab
  • Kinase Inhibitor
    • Crizotinib
    • Ceritinib
  • Epidermal Growth Factor Receptor Blocker
    • Erlotinib
    • Afatinib
    • Gefitinib
  • PD-1/ PD-L1 Inhibitor
    • Nivolumab
    • Pembrolizumab
  • Folate Antimetabolites
    • Pemetrexed
    • Others
  • Large Cell (Undifferentiated) Carcinoma
  • Squamous Cell (Epidermoid) Carcinoma
  • Adenocarcinoma
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Bristol-Myers Squibb (U.S)
  • AstraZeneca plc (U.K)
  • Celgene Corporation (U.S)
  • Boehringer Ingelheim (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S)
  • Eli Lilly and Company (U.S)
  • Roche(Switzerland)
  • Merck & Co.(U.S)
  • Agennix AG (Germany)